Physician profile
Anthony W Brown
NPI 1417097361
$15,638.14
in general payments reported to CMS, 2019-2025
60 companies · $2,485 in 2025
The $2,485 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,012 · 2020: $1,389 · 2021: $2,763 · 2022: $2,738 · 2023: $2,767 · 2024: $2,484 · 2025: $2,485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,552 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,552.13 |
| Education | $184.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,139.52 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $2,099.45 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,879.50 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $830.35 | 2020-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $745.97 | 2019-2025 | Mounjaro, Jardiance, Kisunla |
| Pfizer INC. | $711.19 | 2019-2025 | |
| Glaxosmithkline, LLC. | $596.22 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $532.86 | 2019-2025 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $393.53 | 2023-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $379.27 | 2019-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $379.11 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Novartis Pharmaceuticals Corporation | $378.52 | 2019-2025 | |
| Amgen INC. | $316.82 | 2019-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $270.80 | 2021-2023 | |
| Mannkind Corporation | $265.57 | 2019-2023 | Afrezza |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.